{
    "xml": "<topic id=\"PHP5082\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/fesoterodine-fumarate\" basename=\"fesoterodine-fumarate\" title=\"FESOTERODINE FUMARATE\">\n<title>FESOTERODINE FUMARATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1119\" namespace=\"/interactions/list-of-drug-interactions/antimuscarinics/fesoterodine\">Fesoterodine</xref>\n</p>\n<data name=\"vtmid\">432254002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_567112641\" title=\"Antimuscarinics\">Antimuscarinics</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34659\" title=\"ANTIMUSCARINICS (SYSTEMIC)\" namespace=\"/drug-classes/antimuscarinics-systemic\">ANTIMUSCARINICS (SYSTEMIC)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP61749\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Urinary frequency</p>\n<p outputclass=\"therapeuticIndication\">Urinary urgency</p>\n<p outputclass=\"therapeuticIndication\">Urge incontinence</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>4&#8239;mg once daily, increased if necessary up to 8&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Max. 4&#8239;mg daily with concomitant atazanavir, clarithromycin, indinavir, itraconazole, ritonavir, saquinavir, or telithromycin.</p>\n<p>In patients with hepatic or renal impairment, consult product literature before concomitant use with amprenavir, aprepitant, atazanavir, clarithromycin, diltiazem, erythromycin, fluconazole, fosamprenavir, indinavir, itraconazole, ritonavir, saquinavir, telithromycin, verapamil, or grapefruit juice.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61646\" outputclass=\"sideEffects\" rev=\"1.15\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Insomnia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Cough</ph>; <ph outputclass=\"sideEffect\">nasal dryness</ph>; <ph outputclass=\"sideEffect\">pharyngolaryngeal pain</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61718\" outputclass=\"pregnancy\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61855\" outputclass=\"breastFeeding\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61764\" outputclass=\"hepaticImpairment\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Manufacturer advises increase dose cautiously; max. 4&#8239;mg daily in moderate impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n<p>Consult product literature before concomitant use of cytochrome P450 enzyme inhibitors.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61676\" outputclass=\"renalImpairment\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Increase dose cautiously if eGFR 30&#8211;80&#8239;mL/minute/1.73m<sup>2</sup>; max. 4&#8239;mg daily if eGFR less than 30&#8239;mL/minute/1.73m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Consult product literature before concomitant use of cytochrome P450 enzyme inhibitors.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59526\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61532\" outputclass=\"nationalFunding\" rev=\"1.11\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium </i> has advised (June 2008) that fesoterodine (<i>Toviaz</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland as a second-line treatment for overactive bladder syndrome.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5082-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/fesoterodine-fumarate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77121\" title=\"Modified-release tablet\" namespace=\"/drugs/fesoterodine-fumarate/modified-release-tablet\">Modified-release tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78573\" namespace=\"/treatment-summaries/urinary-frequency-enuresis-and-incontinence\" title=\"Urinary frequency, enuresis and incontinence\" count=\"1\" rel=\"backlink\">Urinary frequency, enuresis and incontinence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1119\" namespace=\"/interactions/list-of-drug-interactions/antimuscarinics/fesoterodine\" title=\"Fesoterodine\" count=\"1\" rel=\"link\">Fesoterodine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34659\" namespace=\"/drug-classes/antimuscarinics-systemic\" title=\"ANTIMUSCARINICS (SYSTEMIC)\" count=\"1\" rel=\"link\">ANTIMUSCARINICS (SYSTEMIC)</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77121\" namespace=\"/drugs/fesoterodine-fumarate/modified-release-tablet\" title=\"Modified-release tablet\" count=\"1\" rel=\"link\">Modified-release tablet</xref>\n</links>\n</topic>",
    "id": "PHP5082",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/fesoterodine-fumarate",
    "basename": "fesoterodine-fumarate",
    "title": "FESOTERODINE FUMARATE",
    "interactants": [
        {
            "id": "bnf_int_1119",
            "label": "Fesoterodine"
        }
    ],
    "vtmid": "432254002",
    "drugClassification": [
        "Antimuscarinics"
    ],
    "inheritsFromClass": [
        "ANTIMUSCARINICS (SYSTEMIC)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Urinary frequency",
                        "html": "Urinary frequency"
                    },
                    {
                        "textContent": "Urinary urgency",
                        "html": "Urinary urgency"
                    },
                    {
                        "textContent": "Urge incontinence",
                        "html": "Urge incontinence"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "4 mg once daily, increased if necessary up to 8 mg once daily.",
                        "html": "<p>4&#8239;mg once daily, increased if necessary up to 8&#8239;mg once daily.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Max. 4 mg daily with concomitant atazanavir, clarithromycin, indinavir, itraconazole, ritonavir, saquinavir, or telithromycin. In patients with hepatic or renal impairment, consult product literature before concomitant use with amprenavir, aprepitant, atazanavir, clarithromycin, diltiazem, erythromycin, fluconazole, fosamprenavir, indinavir, itraconazole, ritonavir, saquinavir, telithromycin, verapamil, or grapefruit juice.",
                "html": "<p>Max. 4&#8239;mg daily with concomitant atazanavir, clarithromycin, indinavir, itraconazole, ritonavir, saquinavir, or telithromycin.</p> <p>In patients with hepatic or renal impairment, consult product literature before concomitant use with amprenavir, aprepitant, atazanavir, clarithromycin, diltiazem, erythromycin, fluconazole, fosamprenavir, indinavir, itraconazole, ritonavir, saquinavir, telithromycin, verapamil, or grapefruit juice.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Insomnia",
                        "html": "Insomnia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Cough",
                        "html": "Cough",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nasal dryness",
                        "html": "nasal dryness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pharyngolaryngeal pain",
                        "html": "pharyngolaryngeal pain",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Manufacturer advises increase dose cautiously; max. 4 mg daily in moderate impairment.",
                "html": "<p>Manufacturer advises increase dose cautiously; max. 4&#8239;mg daily in moderate impairment.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.\n\nConsult product literature before concomitant use of cytochrome P450 enzyme inhibitors.",
                "html": "<p>Avoid in severe impairment.</p><p>Consult product literature before concomitant use of cytochrome P450 enzyme inhibitors.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Increase dose cautiously if eGFR 30&#8211;80 mL/minute/1.73m2; max. 4 mg daily if eGFR less than 30 mL/minute/1.73m2.",
                "html": "<p>Increase dose cautiously if eGFR 30&#8211;80&#8239;mL/minute/1.73m<sup>2</sup>; max. 4&#8239;mg daily if eGFR less than 30&#8239;mL/minute/1.73m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Consult product literature before concomitant use of cytochrome P450 enzyme inhibitors.",
                "html": "<p>Consult product literature before concomitant use of cytochrome P450 enzyme inhibitors.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.",
                "html": "<p>The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (June 2008) that fesoterodine (Toviaz ) is accepted for restricted use within NHS Scotland as a second-line treatment for overactive bladder syndrome.",
                "html": "<p>The <i>Scottish Medicines Consortium </i> has advised (June 2008) that fesoterodine (<i>Toviaz</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland as a second-line treatment for overactive bladder syndrome.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77121",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78573",
                "label": "Urinary frequency, enuresis and incontinence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1119",
                "label": "Fesoterodine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34659",
                "label": "ANTIMUSCARINICS (SYSTEMIC)",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77121",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            }
        ]
    }
}